BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27351277)

  • 1. Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.
    Prentoe J; Velázquez-Moctezuma R; Foung SK; Law M; Bukh J
    Hepatology; 2016 Dec; 64(6):1881-1892. PubMed ID: 27351277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
    Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
    PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.
    Prentoe J; Serre SB; Ramirez S; Nicosia A; Gottwein JM; Bukh J
    J Virol; 2014 Feb; 88(3):1725-39. PubMed ID: 24257605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.
    Carlsen TH; Pedersen J; Prentoe JC; Giang E; Keck ZY; Mikkelsen LS; Law M; Foung SK; Bukh J
    Hepatology; 2014 Nov; 60(5):1551-62. PubMed ID: 25043937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.
    Prentoe J; Jensen TB; Meuleman P; Serre SB; Scheel TK; Leroux-Roels G; Gottwein JM; Bukh J
    J Virol; 2011 Mar; 85(5):2224-34. PubMed ID: 21123377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
    Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
    J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations.
    Prentoe J; Velázquez-Moctezuma R; Augestad EH; Galli A; Wang R; Law M; Alter H; Bukh J
    Proc Natl Acad Sci U S A; 2019 May; 116(20):10039-10047. PubMed ID: 31040211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus.
    Olesen CH; Augestad EH; Troise F; Bukh J; Prentoe J
    PLoS Pathog; 2021 Jul; 17(7):e1009720. PubMed ID: 34280245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.
    Vieyres G; Dubuisson J; Patel AH
    J Gen Virol; 2011 Mar; 92(Pt 3):494-506. PubMed ID: 21084495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Infect Dis; 2019 Jan; 219(1):68-79. PubMed ID: 30102355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.
    Alhammad Y; Gu J; Boo I; Harrison D; McCaffrey K; Vietheer PT; Edwards S; Quinn C; Coulibaly F; Poumbourios P; Drummer HE
    J Virol; 2015 Dec; 89(24):12245-61. PubMed ID: 26378182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
    Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T
    Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.
    Pedersen J; Carlsen TH; Prentoe J; Ramirez S; Jensen TB; Forns X; Alter H; Foung SK; Law M; Gottwein J; Weis N; Bukh J
    Hepatology; 2013 Nov; 58(5):1587-97. PubMed ID: 23729237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
    Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV.
    Mosa AI; AbouHaidar MG; Urbanowicz RA; Tavis JE; Ball JK; Feld JJ
    Virol J; 2020 Sep; 17(1):140. PubMed ID: 32948191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.